secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0000950170-25-091693
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA completes Kineta acquisition, adds Phase 2 VISTA mAb TBS-2025
--------------------------------------------------------------------

- Each Kineta share converted into 0.185298 TuHURA shares; ~2.87M shares issued at closing, plus up to ~1.13M additional shares subject to six-month adjustment.
- VISTA-inhibiting antibody renamed TBS-2025; TuHURA plans Phase 2 trial in NPM1 mutated AML in 2H 2025.
- Acquisition unlocks fourth tranche of $12.5M PIPE financing announced June 3, 2025.
- TuHURA believes TBS-2025 can overcome acquired resistance to cancer immunotherapy; exploring ADC synergies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017025091693/0000950170-25-091693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017025091693/hura-20250630.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-091693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer